Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) fell 0% during trading on Tuesday . The company traded as low as $1.91 and last traded at $1.92. 4,396,832 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 7,142,338 shares. The stock had previously closed at $1.92.
A number of brokerages have recently commented on SGYP. Zacks Investment Research lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. BidaskClub upgraded shares of Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 14th. BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of Synergy Pharmaceuticals in a research note on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Synergy Pharmaceuticals in a research note on Thursday, February 1st. Finally, CIBC reiterated a “market perform” rating on shares of Synergy Pharmaceuticals in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Synergy Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $8.28.
The company has a debt-to-equity ratio of -68.13, a current ratio of 4.26 and a quick ratio of 3.88. The firm has a market capitalization of $473.59, a price-to-earnings ratio of -1.66 and a beta of 1.13.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of Synergy Pharmaceuticals in the second quarter worth approximately $101,000. HBK Sorce Advisory LLC purchased a new position in shares of Synergy Pharmaceuticals in the fourth quarter worth approximately $103,000. Sandy Spring Bank purchased a new position in shares of Synergy Pharmaceuticals in the fourth quarter worth approximately $109,000. Advisor Group Inc. boosted its holdings in shares of Synergy Pharmaceuticals by 25.2% in the second quarter. Advisor Group Inc. now owns 25,625 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 5,150 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Synergy Pharmaceuticals in the fourth quarter worth approximately $124,000. 58.09% of the stock is currently owned by institutional investors.
WARNING: “Synergy Pharmaceuticals (SGYP) Stock Price Down 0%” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/20/synergy-pharmaceuticals-sgyp-stock-price-down-0.html.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.